| Autor: |
Hutterer KM; Process and Product Development, Amgen Inc., Thousand Oaks, CA USA. hutterer@amgen.com, Hong RW, Lull J, Zhao X, Wang T, Pei R, Le ME, Borisov O, Piper R, Liu YD, Petty K, Apostol I, Flynn GC |
| Jazyk: |
angličtina |
| Zdroj: |
MAbs [MAbs] 2013 Jul-Aug; Vol. 5 (4), pp. 608-13. Date of Electronic Publication: 2013 Apr 18. |
| DOI: |
10.4161/mabs.24725 |
| Abstrakt: |
Manufacturing-induced disulfide reduction has recently been reported for monoclonal human immunoglobulin gamma (IgG) antibodies, a widely used modality in the biopharmaceutical industry. This effect has been tied to components of the intracellular thioredoxin reduction system that are released upon cell breakage. Here, we describe the effect of process parameters and intrinsic molecule properties on the extent of reduction. Material taken from cell cultures at the end of production displayed large variations in the extent of antibody reduction between different products, including no reduction, when subjected to the same reduction-promoting harvest conditions. Additionally, in a reconstituted model in which process variables could be isolated from product properties, we found that antibody reduction was dependent on the cell line (clone) and cell culture process. A bench-scale model using a thioredoxin/thioredoxin reductase regeneration system revealed that reduction susceptibility depended on not only antibody class but also light chain type; the model further demonstrates that the trend in reducibility was identical to DTT reduction sensitivity following the order IgG1λ > IgG1κ > IgG2λ > IgG2κ. Thus, both product attributes and process parameters contribute to the extent of antibody reduction during production. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
